Cutaneous Tuberculosis. Mycobacterium There are approximately 30 species of Mycobacterium that cause disease in humans. The primary culprits include M. - презентация

1 Cutaneous Tuberculosis

2 Mycobacterium There are approximately 30 species of Mycobacterium that cause disease in humans. The primary culprits include M. tuberculosis complex, M. leprae, and atypical mycobacteria M. tuberculosis complex include: M.tuberculosis, M.bovis, and M.africanum.

3 Definition Tuberculosis is a systemic infectious disease that can affect any organ system, including the skin Cutaneous tuberculosis (CT) has a broad clinical spectrum depending on the route of infection, virulence of the organism, and immune status of the host

4 Etiology The obligate human pathogenic mucobacteria: M.tuberculosis, M.bovis and, occasionally, bacillus Calmette- Guerin (BCG) These are acid-fast, weakly gram-positive, nonsporulating and nonmotile rods.

5 Classification of CT Exogenous: - Primary inoculation tuberculosis - Tuberculosis verrucosa cutis Endogenous: - Scrofuloderma - Orificial tuberculosis Hematogenous/lymphatic: - Lupus vulgaris - Acute miliary tuberculosis

6 Route of CT infection Exogenous infection is acquired from an outside source: primary inoculation tuberculosis as a primary infection in a non-immune host; tuberculosis verrucosa cutis as a secondary infection in an immune host Endogenous spread as organisms are passed from internal organ involvement: scrofuloderma by contiguous spread; orificial tuberculosis by autoinoculation Through hematogenous or lymphatic dissemination: lupus vulgaris and miliary tuberculosis.

7 Histopathology The tubercle is the histopathologic hallmark of tuberculosis; it consists of giant cells, epithelioid cells and may have varying amounts of caseation necrosis.

8 Primary inoculation tuberculosis: clinical manifestations Initially, papule occurs at the inoculation site 2 to 4 weeks after the wound. Lesions enlarges to a painless ulcer, so called tuberculous chancre (up to 5 cm), with shallow granular base and multiple tiny abscesses or may be covered by thick crust. Undermined margins; deeper inoculation results in subcutaneous abscess Most common on exposed skin at sites of minor injuries Oral lesions occur after ingestion of bovine bacilli in non-pasteurized milk; intra-oral inoculation results in ulcers on gingiva or palate Regional lymphadenopathy occurs within 3 to 8 weeks.

9 Tuberculosis verrucosa cutis: clinical manifestations Initial papule with violaceous halo Evolves to hyperkeratotic, warty, firm plaque Clefts and fissures occur from which pus and keratinous material can be expressed Border often irregular; lesions are usually single, most commonly on dorsolateral hands and fingers In children, lower extremities, knees No lymphadenopathy.

10 Scrofuloderma: clinical manifestations Firm subcutaneous nodule that initially is freely movable; the lesion then becomes doughy and evolves into an irregular, deep-seated node or plaque that liquefies and perforates. Ulcers and irregular sinuses, usually of linear or serpiginous shape, discharge pus or caseous material. Edges are undermined, inverted, and dissecting subcutaneous pockets alternating with soft, fluctuating infiltrates and bridging scars. Most often occurs in the parotidal, submandibular, and supraclavicular regions; lateral neck. Scrofuloderma most often results from continuous spread from affected lymph nodes or tuberculous bones (phalanges, sternum, ribs) or joints.

11 Orificial tuberculosis: clinical manifestations Small yellowish nodule on mucosa breaks down to form painful circular or irregular ulcer with undermined borders and pseudomembranous material, yellowish tubercles, and eroded vessels at its base. Surrounded mucosa is swollen, edematous, and inflamed. Since orificial tuberculosis results from autoinoculation of mycobacteria from progressive tuberculosis of internal organs, it is usually found on the oral, pharyngeal (pulmonary tuberculosis), vulvar (genitourinary tuberculosis), and anal (intestinal tuberculosis) mucous membranes. Lesions may be single or multiple, and in the mouth most often occur on the tongue, soft and hard palate, or lips.

12 Lupus vulgaris: clinical manifestations Initial flat papule is ill-defined, irregular plaque Reddish-brown: diascopy (the use of a glass slide pressed against the skin) reveals an apple jelly (yellowish-brown color) The consistency is characteristically soft; if the lesion is probed, the instruments breaks through the overlying epidermis Surface is initially smooth or slightly scaly but may become hyperkeratotic Hypertrophic forms result in soft tumorous nodules Ulcerative forms present al punched-out, often serpiginous ulcers surrounded by soft, brownish infiltrate Usually solitary, but several sites may occur Most lesions on the head and neck, most often on nose and ears or scalp Involvement of underlying cartilage but not bone results in its destruction (ears, nose) Scarring is prominent and characteristically new brownish infiltrates occur within atrophic scars.

13 Acute miliary tuberculosis: clinical manifestations Exanthem: disseminated lesions are minute macules and papules or purpuric lesions; sometimes are vesicular and crusted. Removal of crust reveals umbilication. Disseminated on all parts of the body, particularly the trunk.

14 Laboratory examinations Dermatopathology: epithelioid cells, Langhans giant cells, lymphocytes, caseation necrosis – tubercle pattern Culture: possible in case of lupus vulgaris or warty tuberculosis PCR: standard procedure to identify M.tuberculosis DNA in tissue specimens. PPD: tuberculin Purified Protein Derivative is an intracutaneous skin test (idr). Skin testing consists of intradermal injection into the volar surface of the forearm (Mantoux method).

15 Treatment First-line essential antituberculous drugs: isoniazid, rifampin, and rifabutin. First-line supplemental antituberculous drugs: pyrazinamide, ethambutol and streptomycine. Second line antituberculous drugs. 6 months protocol: an intensive 2 months therapy with four agents followed by 4 months therapy with isoniazid and rifampin.

16 Leprosy (Hansens disease) Definition: is a chronic granulomatous disease caused by Mycobacterium leprae and principally acquired during childhood or young adulthood. The skin, mucous membranes of the upper respiratory tract, and peripheral nerves are the major sites involvement in all form of leprosy. The clinical manifestations, natural history, and prognosis of leprosy are related to the host response; and the various types of leprosy represent the spectra of the hosts immunologic response (cell-mediated immunity).

17 Etiology M. leprae is a slender, straight, or slightly curved, acid-fast rod, about 3-5 micrometers The organism cannot be cultured in vitro

18 Leprosy Classification (clinicopathologic) Tuberculoid (TL): localized skin involvement and/or peripheral nerve involvement; few organisms are present in the skin biopsies. Lepromatous (LL): generalized involvement including skin, upper respiratory mucous membrane, the reticuloendothelial system, adrenal glands, and testes; many bacilli are present in tissue. Borderline (dimorphic) (BB): has features of both tuberculoid and lepromatous leprosy; usually many bacilli are present; varied skin lesions – macules, plaques; progresses to TL or regresses to LL. Indeterminate and transitional forms.

19 Transmission Mode of transmission is uncertain; however, human-to-human transmission is the norm The main source is the individuals with multibacillary-type infection, shedding several millions of bacilli per day in nasal and upper respiratory tract Portals of entry include ingestion of food and drink, inoculation into or through skin (bites, scratches, tattoos, small wounds), or inhalation into nasal passages or lungs.

20 Pathogenesis The clinical spectrum of leprosy depends exclusively on variable limitations in the hosts capability to develop effective cell-mediated immunity to M.leprae. The organism is capable of invading and multiplying in peripheral nerves and infecting and surviving in endothelial and phagocytic cells in many organs. Clinical expression of leprosy is the development of a granuloma. The granulomatous spectrum of leprosy consists of a high-resistance tuberculoid pole (TT), a low or absent- resistance lepromatous pole (LL), a dimorphic or borderline region (BB) and two intermediary regions: borderline lepromatous (BL) and borderline tuberculoid (BT). In order of decreasing resistance: TT>BT>BB>BL>LL.

21 Immunologic responses Immune responses to M.leprae can produce several types of reactions associated with a sudden change in the clinical status: - Lepra type 1 reactions: individuals with BT and BL develop inflammation within existing skin lesions before therapy or in response to therapy; can be associated with low-grade fever, new multiple small satellite maculopapular skin lesions and/or neuritis - Lepra type 2 reactions: seen in half of LL patients, usually occurring after initiation of antilepromatous therapy, generally within the first 2 years of treatment; massive inflammation with erythema nodosum-like lesions - Lucios reaction: individuals with diffuse LL develop shallow, large polygonal sloughing ulcerations on the legs; the ulcers heal poorly, recur frequently, and may occur in a generalized distribution; generalized Lucios reaction is frequently complicated by secondary bacterial infection and sepsis.

22 Tuberculoid Leprosy: clinical presentation A few well-defined hypo-pigmented anesthetic macules with raised edges and varying in size from a few millimeters to very large lesions covering the entire trunk; Erythematous or purple border and hypopigmented center; Lesions are sharply defined, raised, often annular and involve any site including face. Nerve involvement: may be a thickened nerve on the edge of the lesion; large peripheral nerve enlargement frequent (ulnar).

23 Lepromatous Leprosy: clinical presentation Small erythematous or hypopigmented macules that are anesthetic; later papules, plaques, nodules, and diffuse thickening of the skin, with loss of hair (eyebrows and eyelashes). Leonina facies (lions face) due to thickening, nodules, and plaques distort normal facial features Normal skin color or erythematous or slightly hypopigmented Distribution of lesions: bilaterally symmetric involving earlobes, face, arms, and buttocks, or less frequently the trunk and lower extremities; tongue involvement with nodules, plaques and fissures. Eye involvement: the anterior chamber can be invaded with resultant glaucoma and cataract formation; corneal damage, sensory neuropathy and muscle paralysis can occur Testes involvement: resultant hypogonadism.

24 Borderline Leprosy: clinical presentation Lesions are intermediate between tuberculoid and lepromatous and comprised of macules, papules, and plaques Anesthesia and decreased sweating are prominent in the lesions Reactional phenomenon: - lepra type 1 reaction – skin lesions become acutely inflamed associated with edema and pain; may ulcerate; edema most severe on face, hands, and feet - lepra type 2 reaction – present as painful red skin nodules; lesions form abscesses or ulcerate; lesions occur most commonly on face and extensor limbs. - Lucios reaction – presents as irregularly shaped erythematous plaques; lesions may resolve spontaneously or undergo necrosis with ulceration.

25 Complications Contractures and trophic changes in the hands and feet Secondary amyloidosis with renal failure Lepra type 2 reactions may be complicated by uveitis, dactylitis, arthritis, neuritis, lymphadenitis, myositis, orchitis Lucios reaction: vasculitis with subsequent infarction

26 3 mainstays of leprosy diagnosis Cutaneous anesthesia: using a wisp of cotton to demonstrate loss of light touch; in TL and BL within the center of the lesion, while in LL occurs first in fingers and toes; Nerve enlargement: in TL and BL occurs within or adjacent to specific skin lesions, while in LL large peripheral nerves can be palpated (posterior auricular nerve, ulnar nerve, etc.) The demonstration of M.leprae in the skin: accomplished by a slit skin smear)

27 Laboratory examinations Slit-skin smears: a small incision is made; the site then scraped to obtain tissue fluid from which a smear is made and examined after Ziehl-Neelsen staining; specimens are usually obtained from both earlobes and two other active lesions Nasal smears or scrapings Culture: M.leprae has not been cultured in vitro; routine bacterial cultures to rule out secondary infection PCR: M.leprae DNA detected by this technique makes the diagnosis of early paucibacillary leprosy and identifies the germen after the treatment Dermatopathology: TL shows epithelioid cell granulomas forming around dermal nerves and acid-fast bacilli are sparse or absent; LL shows an extensive cellular infiltrate separated from the epidermis by a narrow zone of normal collagen, skin appendages are destroyed, macrophages are filled with M.leprae, having abundant foamy cytoplasm (lepra Virchow cells) Lepromin skin test: an intradermal injection of 0.1 ml of lepromin is read at 48 hours for erythema (Fernandez reaction) or at 3-4 weeks for a papule or nodule (Mitsuda reaction); in TL – strongly positive reaction, while in BL and LL is usually negative.

28 Antilepromatous Therapy (paucibacillary disease: TT and BT) Minimum 6 months treatment duration: Rifampin 600 mg / month Dapsone 100 mg / day Post-treatment follow-up duration: minimum of 2 years with clinical exams at least every 12 months

29 Antilepromatous Therapy (multibacillary disease: LL, BL and BB) Minimum of 2 years treatment duration: Rifampin 600 mg / month Clofazimine, 300 mg / month Dapsone 100 mg / day Clofazimine, 50 mg / day Post-treatment follow-up duration: minimum of 5 years with clinical and bacteriological exams at least every 12 months